Innosphere Launches Investor Network

Wednesday, April 19, 2017

Colorado - Innosphere, Colorado's leading incubator for science and technology startups, has formally launched an investor network to support investment into Innosphere client companies. The Innosphere Investor Network is a group of active, accredited investors seeking highly-vetted, investment-ready opportunities. 

CereScan's Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

Tuesday, April 11, 2017

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders. Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity. The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide. 

Biodesix Presents Data From Three Studies at AACR Annual Meeting

Wednesday, April 05, 2017

New data on liquid biopsy genomic tests, including multiplexed genomic assays; evaluation of biological processes underlying mass spectrometry proteomic assays of human serum. 

SomaLogic announces the appointment of long-time Board member Alister W. Reynolds as Chief Executive Officer

Wednesday, April 05, 2017

Former CEO Byron Hewett steps down after successfully building the foundation for SomaLogic’s future growth. 

ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

Tuesday, April 04, 2017

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration (CFDA). 

InDevR Collaborates with I&L Biosystems to Market Products in Western Europe

Tuesday, April 04, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, is pleased to announce an exclusive sales, marketing and customer support relationship with I&L Biosystems GmbH and its subsidiaries. The distribution agreement includes sales and support for the Cypher One™ and soon to launch VaxArray™ product lines throughout Western Europe. 

VetDC Announces Commercial Launch of TANOVEA™-CA1 for Lymphoma in Dogs

Monday, April 03, 2017

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced that TANOVEA™-CA1 (rabacfosadine for injection) is now commercially available in the US for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs. 

New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

Monday, April 03, 2017

BOULDER, Colo., April 03, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC) reduces the aggregate costs of end-of-life treatment while improving survival and quality of life. The data were presented at the American College of Medical Quality (MQ2017) annual meeting, which was held March 29 - April 1 in Washington, DC. 

miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

Friday, March 31, 2017

BOULDER, CO – March 31, 2017 – miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan-drug designation to miRagen’s product candidate, MRG-106, for the treatment of mycosis fungoides. Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma (“CTCL”). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and in other parts of the body. 

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado

Thursday, March 23, 2017

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado